Beekeeper' arthropathy (2022)

ScienceDirect

Corporate sign inSign in / register

ViewPDF

  • Access throughyour institution

Reumatología Clínica (English Edition)

Volume 16, Issue 2, Part 2,

March–April 2020

, Pages 177-179

(Video) Bees. Bee Venom Therapy. Apitherapy. Rheumatoid Arthritis. Polish Beekeeper. Beekeeping. Florida.USA

Abstract

An acute inflammatory arthritis of unknown cause has been described in beekeepers in relation to their work with the hives. We present the case of a beekeeper who, after a bee sting, developed arthritis of the interphalangeal joint of the first finger of his left hand. Although the subacute clinical course and the magnetic resonance imaging findings required the differential diagnosis with an infectious process, the rest of the laboratory tests. Other imaging studies and the course, together with a history of a similar episode a few years earlier on a finger of the other hand after a bee sting, enabled us to diagnosis this condition.

Resumen

En los apicultores se ha descrito una artropatía inflamatoria de etiología desconocida pero relacionada con su actividad profesional. Se expone el caso de un apicultor que tras la picadura de abeja presentó una artritis de la articulación interfalángica del primer dedo de la mano izquierda. Aunque el curso clínico subagudo y los hallazgos de la RMN obligaban a plantear el diagnóstico diferencial con un proceso infeccioso, el resto de pruebas analíticas, de imagen y la evolución, junto al antecedente de episodio similar unos años antes en un dedo de otra mano tras la picadura de abeja, permitió el diagnóstico de esta entidad.

Introduction

A joint syndrome has been described in beekeepers which consists of a recurrent, non infectious arthritis, of the small joints of the hand after exposure to bee stings. We present the case of a beekeeper who was referred to us for examination and treatment for acute arthritis in the interphalangeal joint of the thumb of his left hand.

Section snippets

Clinical case

A 58-year-old beekeeper, with no history of interest presented at the surgery after a bee sting due to swelling and erythema in the interphalangeal joint (IP) of the thumb of his left hand, of 3-week onset (Fig. 1A). He did not present with a fever at any time. During anamnesis he also referred to the fact that after an insect (bee) sting 4 years ago he had also suffered from a similar previous inflammation of one finger of his right hand, for a month. In the plain X-ray the increases of soft

Discussion

In beekeepers the appearance of episodes of arthritis in their work in hives has been described. The first case of the so-called “beekeeper's arthropathy” was published in Spain in 1989,1 after which broader series have been published like, for example, a descriptive clinical study in beekeepers in “The Siberian Extremadura”.2 It has been estimated that this condition may affect up to 32%–43% of them.3 The episodes consist of acute or subacute asymmetrical arthropathy, which affect one or

Conclusion

When faced with an acute or subacute episode of arthritis which affects the hands of a patient who works as a beekeeper we should bear in mind that this entity during differential diagnosis and question them about the background of the bee sting and whether they have suffered from any previous similar episodes.

Conflict of interests

The authors have no conflict of interests to declare.

References (5)

  • E. Villanueva-García et al.Artropatía del apicultor

    Rev Ortop Traumatol

    (2005)

  • J. Peña

    Avances en el estudio del síndrome artrítico de los apicultores

    Vida Apícola

    (1989)

There are more references available in the full text version of this article.

(Video) Dr. Max Gomez: Bee Therapy For Arthritis

Cited by (0)

Recommended articles (6)

  • Research article

    Methylation Status of Interleukin-6 Gene Promoter in Patients with Behçet's Disease

    Reumatología Clínica (English Edition), Volume 16, Issue 3, 2020, pp. 229-234

    IL-6 mRNA expression is significantly high in many autoimmune diseases such as Behçet's disease; this is often related with more aggressive phenotypes. Nevertheless, the essential molecular process for its high expression has not been completely realized. The aim of this study was undertaken to estimate the gene copy number variation and promoter methylation to IL-6's high expression.

    This study was performed on 51 patients and 61 healthy controls. Initially, DNA and RNA were extracted from all specimens. Promoter methylation levels of IL-6 were evaluated by MeDIP-qPCR technique. Also, IL-6 gene expression was measured by Real-time PCR. After that, we evaluated the relationship between gene expression and methylation, as well as their relationship with clinical specification.

    As we expected, the expression level of IL-6 gene increased significantly in the patient group compared to the healthy subjects. Also, the relative promoter methylation level of the IL-6 mRNA was significantly lower in patient group compared to healthy group (p<0.001).

    We disclosed that the promoter hypomethylation may be considered as one of the main defects for IL-6 mRNA high expression in patients with Behçet's disease.

    La expresión de ARNm de IL-6 es significativamente elevada en muchas enfermedades autoinmunes, tales como el síndrome de Behçet, y ello se relaciona a menudo con fenotipos más agresivos. Sin embargo, no se ha comprendido plenamente el proceso molecular esencial para esta expresión elevada. El objetivo de este estudio fue la estimación de la variación del número de copias del gen, y la metilación del promotor de la expresión elevada de IL-6.

    Este estudio se realizó en 51 pacientes y 61 controles sanos. Al inicio, se extrajo ADN y ARN de todas las muestras. Se evaluaron los niveles de metilación del promotor de IL-6 mediante la técnica MeDIP-qPCR. También se midió la expresión del gen IL-6 mediante PCR a tiempo real. Tras ello, evaluamos la relación entre la expresión del gen y la metilación, así como su relación con la especificación clínica.

    Según lo previsto, el nivel de expresión del gen IL-6 se incrementó significativamente en el grupo de pacientes, con respecto a los sujetos sanos. También encontramos que el nivel relativo de metilación del promotor de ARNm de IL-6 fue considerablemente menor en el grupo de pacientes, con respecto al grupo sano (p<0,001).

    Concluimos que la hipometilación del promotor puede considerarse uno de los defectos principales de la expresión elevada de ARNm de IL-6, en los pacientes con síndrome de Behçet.

  • Research article

    Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital

    Reumatología Clínica (English Edition), Volume 16, Issue 2, Part 1, 2020, pp. 97-102

    Vaccination coverage for seasonal influenza and pneumococcus in rheumatology patients receiving biological treatment. To identify variables that predict vaccination adherence.

    Descriptive cross-sectional study. The study involved rheumatology patients who initiated biological therapy between 01/01/2016 and 12/31/2016 in a regional referral hospital. Variables included sociodemographic information, diagnostic data, treating physician, referral to the vaccine unit and vaccination against pneumococcus with 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), as well as seasonal influenza (2016/17). Univariate, bivariate (Chi-square) and multivariate analysis (logistic regression) were performed. The differences were considered significant (P<.05) and the PASW v.18 software package was used.

    In all, 222 patients were included. Vaccination coverage was: PCV13, 80.2%; PPSV23, 77.9%; influenza 2016/17, 78.8%; PCV13+PPSV23, 75.2%; PCV13+PPSV23+influenza 2016/17, 68.9%. Axial spondylitis had the highest coverage (>80%) for pneumococcal vaccination and combination of pneumococcal with influenza. Overall, 27% of the patients were not referred to the unit. The treating physician was associated with statistical significance in each vaccine alone or combined, but referral to the vaccine unit was independently associated with the highest vaccination coverage (P<.001) in all cases.

    Compared to the scientific literature, we consider that the coverage of our patients against pneumococcus and influenza is high. Referral of these patients to the vaccine unit is the key to guarantee a correct immunization and to minimize some of the possible infectious adverse effects of biological therapies.

    Conocer las coberturas de vacunación frente a gripe estacional y neumococo en pacientes reumatológicos con terapia biológica. Identificar las variables que predicen adherencia a la vacunación.

    Estudio transversal. Se incluyeron los pacientes reumatológicos que iniciaron terapia biológica entre el 01/01/2016 y el 31/12/2016 en un hospital autonómico de referencia. Se recogieron variables sociodemográficas, relacionadas con el diagnóstico, médico prescriptor, derivación a la Unidad de Vacunas y vacunación frente a neumococo con vacuna conjugada de 13 serotipos (VNC13) y polisacárida de 23 serotipos (VNP23), así como gripe estacional (2016/17). Se realizó análisis univariante, bivariante (Chi-cuadrado) y multivariante (regresión logística). Se consideró significativa una p<0,05 y se utilizó el programa PASW v.18.

    Se incluyeron 222 pacientes. Las coberturas de vacunación fueron: VNC13, 80,2%; VNP23v, 77,9%; gripe 2016/17, 78,8%; VNC13+VNP23, 75,2%; VNC13+VNP23+gripe 2016/17, 68,9%. La espondilitis axial registró las coberturas más altas (>80%) para la vacunación antineumocócica y en combinación con la antigripal. El 27% de los pacientes no fueron derivados a la Unidad. El médico prescriptor se asoció de manera estadísticamente significativa con cada una de las vacunas y sus combinaciones, pero fue la derivación a la Unidad de Vacunas la que se asoció de manera independiente con las mayores coberturas de vacunación (p<0,001) en todos los casos.

    Comparando con la literatura científica, consideramos que las coberturas frente a neumococo y gripe en estos pacientes son elevadas. La derivación de estos pacientes a la Unidad de Vacunas resulta clave para garantizar una correcta inmunización y minimizar así algunos de los posibles efectos adversos infecciosos de las terapias biológicas.

    (Video) #213 Colin has new painkilling arthritis drug and bees out and about
  • Research article

    Assessing treatment tolerability for rheumatoid arthritis. Validation and practical applications of the ‘TOL-AR-18 questionnaire’

    Reumatología Clínica (English Edition), Volume 16, Issue 2, Part 2, 2020, pp. 149-155

    Given the lack of standardized tools to assess tolerability from patient's perspective, we carried out the validation of a questionnaire to asses treatment tolerability for rheumatoid arthritis (RA): TOL-AR-18.

    The TOL-AR-18 was validated in the cross-sectional observational study in adult patients with RA. Socio-demographic and clinical variables were collected. Patients completed the TOL-AR-18 and ARTS questionnaires and a question about their general health status.

    Data of 66 patients with a mean age (standard deviation; SD) of 56.71 (10.50) years were analyzed; 66.7% were women. Mean (SD) time to disease progression was 10.76 (8.23) years, and time from first treatment initiation was 9.24 (7.70) years. Patients did not report other adverse events rather than those included in the TOL-AR-18. The questionnaire was feasible with high internal consistency (Cronbach's α >0.90). Discriminant validity was moderate, with significant differences between patients in remission and all other, and between patients who did not report adverse events and the rest (P<.05). Convergent validity was moderate–low when correlated with the ARTS questionnaire.

    The TOL-AR-18 is valid for use in a clinical setting and useful as an additional tool for all professionals to manage and assess tolerability in RA.

    La ausencia de herramientas estandarizadas para evaluar la tolerabilidad desde la perspectiva del paciente, planteó la posibilidad de validar el cuestionario TOL-AR-18 de tolerabilidad al tratamiento de la artritis reumatoide (AR) y evaluar su aplicación en la práctica clínica.

    El desarrollo del cuestionario se realizó siguiendo la metodología estandarizada y posteriormente se validó mediante un estudio observacional y transversal con pacientes >18 años diagnosticados de AR, en tratamiento durante al menos 3 meses. Se recogieron variables socio-demográficas y clínicas. Los pacientes completaron los cuestionarios TOL-AR-18, ARTS, y el cuestionario sobre el estado de salud percibida.

    Se analizaron datos de 66 pacientes de edad media (desviación estándar [DE]) de 56,71 (10,50) años; un 66,7% eran mujeres y el 65,1% presentaba remisión/baja actividad por DAS28. La media (DE) del tiempo de evolución y del inicio del primer tratamiento fue de 11,34 (9,41) y 9,24 (7,7) años, respectivamente. Los pacientes no reportaron reacciones adversas adicionales a las incluidas en el TOL-AR-18. El cuestionario resultó factible con una consistencia interna elevada (α de Cronbach>0,9). La validez discriminante fue moderada, con diferencias estadísticamente significativas entre pacientes en remisión y el resto, y entre quienes no reportaban reacciones adversas y el resto (p<0,05). La validez convergente fue moderada-baja al correlacionarse con el cuestionario ARTS.

    (Video) Do you dare to treat arthritis with beesbee bees orginal beekeeper

    El cuestionario TOLAR-18 es válido para su uso en la práctica clínica y útil como herramienta complementaria para el manejo y valoración de la tolerabilidad en la AR por parte de todos los profesionales implicados.

  • Research article

    Diagnosis of osteochondromatosis as an incidental finding in revision surgery after failed intramedullary nailing of the hip

    Reumatología Clínica (English Edition), Volume 16, Issue 2, Part 1, 2020, pp. 125-126

  • Research article

    Charcot foot associated with chronic alcoholism in a non-diabetic patient: An unusual association

    Reumatología Clínica (English Edition), Volume 16, Issue 2, Part 1, 2020, pp. 127-128

  • Research article

    Prevalence of clinical and radiological osteoarthritis in knee, hip, and hand in an urban adult population of Mexico City

    Reumatología Clínica (English Edition), Volume 16, Issue 2, Part 2, 2020, pp. 156-160

    Osteoarthritis (OA) is the most prevalent articular disease worldwide, and its prevalence is highly variable depending on the classification criteria, population studied, and/or affected joints considered. Reporting epidemiologic data about clinical and radiological OA prevalence in Mexico has not been done before.

    A descriptive cross-sectional study was carried out with participants of Mexico City, and included both men and women above 40 years of age. All participants were evaluated with radiological and clinical criteria for OA.

    Two hundred and four individuals participated in the study: 80 men (39.2%) and 124 women (60.8%). The average age was 57.4±10.9 years. Using clinical criteria alone, 36 participants were found to have hand OA (17.6%; 95% CI, 13–23.4), 37 with hip OA (18.1%; 95% CI 13.4–24), and 40 with knee OA (19.6%; 95% CI 14.7–25.6). When radiological criteria were used, 51 individuals were reported as having hand OA (25%; 95% CI 19.5–31), 54 with hip OA (26.5%; 95% CI 20.8–32.9), and 52 with knee OA (25.5%; 95% CI 20–31.8). When clinical criteria were used and then corroborated with radiological criteria, the prevalence was 28 individuals with hand OA (13.7%; 95% CI 9.6–19), 31 with hip OA (15.1%; 95% CI 10.9–20.7), and 36 with knee OA 36 (17.6%; 95% CI 12.2–26.2).

    The prevalences found in this study are greater than those found in other studies in Mexico that only report clinical criteria.

    La osteoartritis (OA) es la enfermedad articular más prevalente a nivel mundial; la prevalencia reportada es muy variable ya que depende de los criterios de clasificación, la población estudiada y/o las articulaciones afectadas. Previamente no se habían reportado datos epidemiológicos sobre la prevalencia clínica y radiológica de la OA en México.

    Se realizó un estudio descriptivo y transversal, se incluyeron participantes de cualquier sexo mayores de 40 años de la Ciudad de México, todos ellos fueron evaluados con criterios radiológicos y clínicos para la OA.

    Se analizaron 204 individuos, 80 varones (39,2%) y 124 mujeres (60,8%). La edad promedio fue de 57,4±10,9 años. Usando solo criterios clínicos, 36 participantes tuvieron OA de mano (17,6%, IC 95%, 13–23,4), 37 con OA de cadera (18,1%, IC 95% 13,4–24) y 40 con OA de rodilla (19,6% IC 95% 14,7–25,6). Cuando se utilizaron los criterios radiológicos, se informó que 51 individuos tenían OA de mano (25%: IC 95% 19,5–31), 54 con OA de cadera (26,5% IC 95% 20,8–32,9) y 52 con OA de rodilla (25,5%; IC 95% 20–31,8). Al utilizar criterios clínicos y luego corroborados por criterios radiológicos, la prevalencia fue de 28 individuos con OA de mano (13,7% IC 95% 9,6–19), 31 con OA de cadera (15,1% IC 95% 10,9–20,7) y 36 con OA de rodilla 36 (17,6%; IC 95% 12,2–26,2).

    Las prevalencias encontradas en este estudio son mayores a las encontradas en otros estudios en México que solo reportan criterios clínicos.

    (Video) Do you dare to treat arthritis with beesbee bees orginal beekeeper

View full text

© 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Videos

1. Do you dare to treat arthritis with beesbee bees orginal beekeeper
(Bee Bee)
2. Would you dare to treat arthritis with bee stings? #beekeeping #natural #healing
(Marius Andrea)
3. Do you dare to treat arthritis with beesbee bees orginal beekeeper
(Bee Bee)
4. Treatment Free Beekeeping, is it even possible? Frederick Dunn interviews Daniel Weaver of BeeWeaver
(Frederick Dunn)
5. Bee venom and how beekeepers can be prepared for the inevitable sting
(Summit County Beekeepers, Ohio)
6. Beekeeping Without Treatments with Kirk Webster
(Back to the Roots Podcast)

You might also like

Latest Posts

Article information

Author: Golda Nolan II

Last Updated: 05/16/2022

Views: 6121

Rating: 4.8 / 5 (78 voted)

Reviews: 93% of readers found this page helpful

Author information

Name: Golda Nolan II

Birthday: 1998-05-14

Address: Suite 369 9754 Roberts Pines, West Benitaburgh, NM 69180-7958

Phone: +522993866487

Job: Sales Executive

Hobby: Worldbuilding, Shopping, Quilting, Cooking, Homebrewing, Leather crafting, Pet

Introduction: My name is Golda Nolan II, I am a thoughtful, clever, cute, jolly, brave, powerful, splendid person who loves writing and wants to share my knowledge and understanding with you.